



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/597/>

---

**Article:**

Firth, A.Y. (2005) Class A drug abuse: an ophthalmologist's problem? *Eye*, 19 (6). pp. 609-610. ISSN: 1476-5454

<https://doi.org/10.1038/sj.eye.6701624>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



White Rose  
university consortium  
Universities of Leeds, Sheffield & York

White Rose Consortium ePrints Repository

<http://eprints.whiterose.ac.uk/>

This is an author produced version of an editorial published in *Eye*. This paper has been peer-reviewed but may not include the final publisher proof-corrections or journal pagination.

White Rose Repository URL for this paper:

<http://eprints.whiterose.ac.uk/archive/00000597/>

The full reference for the final, published paper is:

Firth, A.Y. (2005) *Class A drug abuse: an ophthalmologist's problem?* *Eye*, 19 (6). pp. 609-610

#### Citation

Where possible, the final paper, as published, should be cited.

To refer to the repository paper, the following format may be used:

[Author] [Date] *Title of the paper*. Author manuscript available at: [White Rose Repository URL] [Accessed date].

Published in final edited form as:

[Full reference of published article]

## **Class A drug abuse – An ophthalmologist’s problem?**

The 2002/3 British Crime Survey <sup>1</sup> reported that 3% of all 16 to 59 year olds (equating to around one million people) had used a class A drug in the last year. Use of a class A drug in the 16-24 year old age group (8%) has remained similar since 1996. Use of cocaine and crack cocaine are on the increase. For the first time since 1996 the use of ecstasy has decreased. Poly drug use is not uncommon. During the year 2000/1, 118,500 patients were in treatment with drug misuse agencies and general practitioners. <sup>2</sup> Ocular sequelae from illicit drug use are varied, affecting visual acuity, visual perception, ocular posture or motility, the globe itself or its adnexa. <sup>3</sup> Large studies are not available to allow us to quantify the problem, and many of the reports are of single cases or small case series. However, an awareness of possible problems which may arise from the use of class A drugs may alert the clinician to this as the aetiology of a condition presenting to them.

Cocaine and crack cocaine probably have the highest number of ocular problems reported from their use. Its sympathomimetic effect has led to acute angle-closure glaucoma <sup>4</sup> and its vasoactive properties to spasms of vessels or haemorrhages. These may be retinal or in the brain stem, leading to visual loss, <sup>5</sup> which can be transient, <sup>6</sup> or ocular motility problems. <sup>7</sup> It's use may also lead to cerebral vasculitis. <sup>8</sup> It is the intense vasoconstriction combined with anaesthesia from the intranasal use of cocaine that leads to mucoperichondrial ischaemia and loss of the nasal septum. This may extend to the bony walls of the orbit. Nasolacrimal duct obstruction, orbital cellulitis, and optic neuropathy can result. <sup>9</sup> Motility problems may not necessarily be vascular. Cocaine is known to unmask or exacerbate myasthenia gravis, possibly due to it blocking the sodium channels and slowing presynaptic neuronal transmission. <sup>10</sup>

We may be familiar with the use of cocaine as an anaesthetic agent. Decreased corneal sensitivity, the direct toxic effect of the smoke, neurotrophic changes or vigorous eye rubbing have all been suggested as leading to corneal problems in crack cocaine users which may include corneal ulcers, superficial punctate keratitis and corneal epithelial defects.<sup>11</sup> Cocaine powder may be introduced into the eye in error by contact lens wearers.<sup>12</sup>

Previously in *Eye*<sup>13</sup> I reported the onset of esotropia following heroin withdrawal and this has since been reported by others.<sup>14,15</sup> A change in the angle of deviation in the eso direction at distance, not due to 6<sup>th</sup> nerve palsy or divergence palsy, has been found to occur following a compressed opiate detoxification regime resulting in a distance esotropia in some patients.<sup>16</sup> This may then presumably decompensate to a constant deviation. Kowal et al<sup>14</sup> reported that diplopia was more common following rapid detoxification and so as these programmes gain popularity more patients may present. Diplopia may also result from internuclear ophthalmoplegia following heroin use, and it's resolution on use of naltrexone (an opiate blocker) is suggestive that this occurs due to an active mechanism.<sup>17</sup>

Sight threatening conditions can occur in heroin users. Toxic amblyopia may result from using quinine either as a cutting agent<sup>18</sup> to make the heroin taste bitter and thus of better quality, or to help the muscle cramps in self detoxification attempts.<sup>19</sup>

Metastatic endophthalmitis from the fungus *candida albicans*, transmitted from lemon juice used to prepare the heroin for injection<sup>20</sup> or *aspergillus*, an air borne fungus have been reported.<sup>21</sup>

Amongst the hallucinogenics fewer problems have been reported. Whilst sun gazing under lysergic acid diethylamide (LSD) may lead to solar retinopathy<sup>22</sup> and magic mushrooms to closing in of nearby space,<sup>23</sup> it is perceptual changes which cause the main problems. Palinopsia, trailing phenomena (discontinuous stationary images that trail behind a moving object), hallucinogenic persisting perception disorder (either in the form of flash-backs or longer lasting alterations in perception) may occur years after use and even after a single episode of LSD use.<sup>24-26</sup> Visual perception disorder (hundreds of dots moving over whole visual field), palinopsia and flashbacks have also been reported following use of methylenedioxymethamphetamine (MDMA), commonly known as ecstasy.<sup>27-29</sup> Retinal haemorrhage following ecstasy use, possibly due to a sudden rise in blood pressure, has been reported in a single case.<sup>30</sup> However, a case of bilateral sixth nerve palsy was attributed to either mild cerebral oedema or interaction of MDMA with the serotonin metabolism in the 6<sup>th</sup> nerve.<sup>31</sup>

Thus, it is apparent that a variety of ocular complaints may present to an eye casualty unit or clinic that are the result of use of class A drugs. Clinicians need to be aware of the ocular problems that may be related to drug use in order that pertinent questions may be asked regarding the cause.

Alison Y Firth

Academic Unit of Ophthalmology and Orthoptics

University of Sheffield

UK

a.firth@sheffield.ac.uk

## References

1. Condon J, Smith N. Prevalence of drug use: key findings from the 2002/2003 British Crime Survey. Home Office Findings 229. London: Home Office. 2003.
2. Department of Health. Statistical bulletin. Statistics from the regional drug misuse databases on drug misusers in treatment in England, 2000/01. London: Department of Health, Statistical Bulletin 2001/33. 2001.
3. Firth AY. Ocular sequelae from the illicit use of class A drugs. *Br Orthopt J* 2004; 61: in press.
4. Mitchell JD, Schwartz AL. Acute angle-closure glaucoma associated with intranasal cocaine abuse. *Am J Ophthalmol* 1996; 122: 425-426.
5. Michaelides M, Larkin G. Cocaine-associated central retinal artery occlusion in a young man. *Eye* 2002; 16: 790-792.
6. Libman RB, Masters SR, de Paola A, Mohr JP. Transient monocular blindness associated with cocaine abuse. *Neurology* 1993; 43: 228-9.
7. Nemeth G, McHenry JG, Zeiter JH, et al: Oculomotor abnormalities secondary to crack cocaine. *Ophthalmology* 1993; 100(suppl): 632.
8. Krendel DA, Ditter SM, Frankel MR, Ross WK. Biopsy proven cerebral vasculitis associated with cocaine abuse. *Neurology* 1990; 40: 1092-1094.
9. Alexandrakis G, Tse DT, Roas RH, Johnson TE. Nasolacrimal duct obstruction and orbital cellulitis associated with chronic intranasal cocaine abuse. *Arch Ophthalmol* 1999; 117: 1617-1622.
10. Valmaggia C, Gottlob I. Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil. *Strabismus* 2001; 9: 9-12.
11. Sachs R, Zigelbaum BM, Hersch PS. Corneal complications associated with the use of crack cocaine. *Ophthalmology* 1993; 100: 187-191.

12. Parmar DN, Robinson F, Hunter PA. Microbial keratitis following cocaine abuse in a soft contact lens wearer. *Eye* 1999; 13: 264-265.
13. Firth AY. Heroin withdrawal as a possible cause of acute concomitant esotropia in adults. *Eye* 2001; 15: 189-192.
14. Kowal L, Mee J, Nadkarni S, Kozminsky M, Kalff S. Acute esotropia in heroin withdrawal. In: de Faber J-T (ed) *Progress in Strabismology, Proceedings of the 10th International Strabismological Association, Sydney, Australia, April 2002*. Swets & Zeitlinger, Lisse. 2003: 305-306.
15. Sutter FKP, Landau K: Heroin and Strabismus. *Swiss Med Wkly* 2003; 133: 293-294.
16. Firth AY, Pulling S, Carr MP, Beaini AY. Orthoptic status pre and immediately post heroin detoxification. *Br J Ophthalmol* 2004; 88: in press.
17. Rizzo M, Corbett J. Bilateral internuclear ophthalmoplegia reversed by naloxone. *Arch Neurol* 1983; 40: 242-243.
18. Brust JCM, Richter RW. Quinine amblyopia related to heroin addiction. *Annals of Internal Medicine* 1971; 74: 84-86.
19. Feeney GFX, Lee GA, O'Connor PA. Quinine-induced blindness during attempted heroin withdrawal. *Med J Australia* 1999; 170: 449.
20. Martinez-Vazquez C, Fernandez-Ulloa J, Borden J. *Candida albicans* endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. *Clin Infect Dis* 1998; 27: 1130-1133.
21. Sugar HS, Mandell GH, Shalev J. Metastatic endophthalmitis associated with injection of addictive drugs. *Am J Ophthalmol* 1971; 71: 1055-1058.
22. Schatz H, Mendelblatt F. Solar retinopathy from sun-gazing under the influence of LSD. *Br J Ophthalmol* 1973; 57: 270-273.

23. Fischer R, Hill R, Thatcher K, Sceib J. Psilocybin-induced contraction of nearby visual space. *Agents and actions* 1970; 1: 190-197.
24. Asher H. 'Trailing' phenomenon – a long-lasting LSD side effect. *Am J Psychiatry* 1971; 127: 1233-1234.
25. Horowitz MJ. Flashbacks: recurrent intrusive images after the use of LSD. *Am J Psychiatry* 1969; 126: 565-9.
26. Woody GE. Visual disturbances experienced by hallucinogenic drug abusers while driving. *Am J Psychiat* 1970; 127: 683-686.
27. Passie T, Schneider U, Emrich HM. Persisting continuous visual perception disorder in a chronic MDMA ('ecstasy') user. *Austalian and New Zealand J Psychiatry* 2002; 36: 266-267.
28. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with the use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). *Br J Psychiatry* 1994; 165: 391-395.
29. Creighton FJ, Black DL, Hyde CE. 'Ecstasy' psychosis and flashbacks. *Br J Psychiatry* 1991; 159: 713-715.
30. Jacks AS, Hykin PG. Retinal haemorrhage caused by 'ecstasy'. *Br J Ophthalmol* 1998; 82: 842-843.
31. Schroeder B, Brieden S. Bilateral sixth nerve palsy associated with MDMA ("ecstasy") abuse. *Am J Ophthalmol* 2000; 129: 408-409.